CB-839性质、用途与生产工艺
CB-839 是一种有效的,选择性的,口服生物可利用的 glutaminase 抑制剂,对重组人GAC的 IC50 为 24 nM。Phase 1。
CB-839 exhibits time-dependent and slowly reversible kinetics. IC50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D.
In the mouse TNBC model, single agent CB-839 (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%.
CB-839 (Telaglenastat) 是一种有效的,选择性的,口服生物可利用的 glutaminase 抑制剂,对重组人GAC的 IC50 为 24 nM。CB-839(Telaglenastat)可诱导自噬并具有抗肿瘤活性。Phase 1。
Target | Value |
Glutaminase
(Cell-free assay)
|
24 nM
|
CB-839表现出时间依赖性和缓慢可逆的动力学特性。与rHu-GAC预培养1小时后,CB-839抑制谷氨酰胺酶的IC50值<50 nmol/L,至少比BPTES低13倍。CB-839对三阴性乳腺癌(TNBC)细胞系,HCC-1806,具有抗增殖活性,而对雌激素受体阳性细胞系,T47D,没有抗增殖活性。
在小鼠TNBC模型中,单剂CB-839 (200 mg/kg, p.o.)抑制相对于载体对照61%的肿瘤生长。在小鼠JIMT-1异种移植模型中,CB-839单独用药(200 mg/kg, p.o.)导致相对载体对照54%的肿瘤生长抑制(TGI),CB-839 (200 mg/kg, p.o.)和paclitaxel (10 mg/kg, p.o.)联合用药很大程度上抑制肿瘤的再生长,相对于载体对照,引起100%的肿瘤生长抑制(TGI)。
CB-839
上下游产品信息
上游原料
下游产品